Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹23 Cr.
Stock P/E
8.8
P/B
0.6
Current Price
₹41.8
Book Value
₹ 65.8
Face Value
10
52W High
₹70.5
52W Low
₹ 39
Dividend Yield
0%

Unick Fix-A-Form Overview

Here's a structured overview of Unick Fix-A-Form And Printers Ltd. based on the provided information.

Important Note: The company name "Unick Fix-A-Form And Printers Ltd." strongly suggests a primary business in printing, particularly specialized forms. The provided sector and industry are "Pharmaceuticals & Drugs." This analysis will proceed assuming the company's core operations are in specialized printing and packaging, with a significant potential focus on serving the pharmaceutical sector given the classification. If the company were truly a drug manufacturer, its name would be highly misleading.

1. Business Overview

Unick Fix-A-Form And Printers Ltd. is primarily engaged in the printing business. Given its name, its core operations likely involve specialized printing services, possibly focusing on "Fix-A-Form" type products (which could imply innovative or multi-part business forms, integrated labels, or specialized document solutions). If classified under the "Pharmaceuticals & Drugs" sector, it's highly probable that the company specializes in providing printing and packaging solutions for the pharmaceutical industry. This could include printing of labels, cartons, patient information leaflets (PILs), security printing for anti-counterfeiting measures on drug packaging, and other specialized packaging components required by pharmaceutical manufacturers. The company makes money by selling its printed products and services to its clientele.

2. Key Segments / Revenue Mix

Specific key segments and their revenue contributions are not publicly disclosed based on the limited information. However, based on the company name and industry classification, potential segments could include:

Pharmaceutical Packaging & Leaflet Printing

Specialized Business Forms & Document Solutions

Security Printing (if applicable to prevent counterfeiting, especially relevant for pharma)

Commercial Printing (general, if diversified)

3. Industry & Positioning

If primarily a specialized printing and packaging company serving the pharmaceutical sector, Unick operates in a segment of the broader packaging industry that is characterized by stringent quality controls, regulatory compliance, and a need for precision. The pharmaceutical packaging market in India is growing, driven by the expanding healthcare sector, increased drug production, and stricter regulations around product information and anti-counterfeiting. This segment can be less fragmented than general commercial printing.

Positioning: Without specific market share data, it's difficult to ascertain its exact position. It likely competes with other specialized packaging and label printers. Success in this niche often depends on client relationships, quality assurance, regulatory adherence, and potentially proprietary printing technologies or processes (like "Fix-A-Form").

4. Competitive Advantage (Moat)

Potential competitive advantages for Unick could include:

Specialization & Expertise: Deep knowledge and established processes for printing complex pharmaceutical labels, leaflets, and cartons, adhering to regulatory standards.

Client Relationships: Long-standing relationships with pharmaceutical companies, which can have high switching costs due to strict qualification processes for suppliers.

Proprietary Products/Processes: If "Fix-A-Form" represents a unique or patented printing solution, it could offer a niche advantage.

Quality & Compliance: A proven track record of meeting stringent quality and regulatory requirements in the pharmaceutical sector.

5. Growth Drivers

Key factors that can drive Unick's growth over the next 3-5 years include:

Growth of Indian Pharmaceutical Industry: Increased drug production, R&D, and exports will directly drive demand for pharmaceutical packaging and printing services.

Regulatory Changes: Stricter regulations for drug labeling, serialization, and anti-counterfeiting measures (e.g., track and trace) will require specialized printing solutions.

Healthcare Expansion: General expansion of healthcare access and consumption in India.

Premiumization of Packaging: Demand for higher quality, more intricate, or sustainable packaging solutions.

6. Risks

Key business risks for Unick include:

Competition: Intense competition from other specialized packaging and label printers.

Raw Material Price Volatility: Fluctuations in prices of paper, ink, and other printing consumables can impact margins.

Technological Obsolescence: Rapid advancements in printing technology requiring continuous investment.

Regulatory Changes (Adverse): Changes in pharmaceutical packaging regulations could necessitate significant operational adjustments or investments.

Economic Downturn: A slowdown in the broader economy or the pharmaceutical sector could impact demand for printing services.

Dependency on Key Clients: Potential over-reliance on a few large pharmaceutical clients.

7. Management & Ownership

Specific details about the promoters and management quality are not available. In many Indian companies, promoters typically hold significant ownership stakes and often play an active role in management. Without further information, it is not possible to assess management quality or the detailed ownership structure.

8. Outlook

Unick Fix-A-Form And Printers Ltd. appears to operate in a specialized niche within the printing and packaging industry, likely catering to the growing pharmaceutical sector. The bull case rests on its ability to leverage its specialized expertise and client relationships to capitalize on the sustained growth of the Indian pharmaceutical industry and increasing demand for high-quality, compliant packaging. Its focus on specialized forms or products (implied by "Fix-A-Form") could provide a distinct market position. The bear case highlights risks such as intense competition, raw material price volatility, the need for continuous technological upgrades, and potential over-reliance on specific client segments or changing regulatory environments. Its ability to maintain competitive advantages through quality, service, and potentially proprietary solutions will be crucial for sustained performance.

Unick Fix-A-Form Share Price

Live · BSE · Inception: 1993
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Unick Fix-A-Form Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 15 16 15 12 13 17 15 12 15 19
Other Income 0 0 0 0 -0 0 0 0 0 0
Total Income 15 16 15 13 13 17 15 12 15 19
Total Expenditure 12 13 13 11 10 14 13 12 13 16
Operating Profit 3 3 2 1 3 3 2 1 2 3
Interest 1 1 1 1 0 1 1 1 1 1
Depreciation 1 1 1 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 2 2 1 -0 1 2 0 -1 0 1
Provision for Tax 0 0 0 -0 0 0 -0 -0 0 0
Profit After Tax 1 1 1 -0 1 1 1 -1 -0 1
Adjustments 0 -0 0 0 -0 -0 -0 -0 0 -0
Profit After Adjustments 1 1 1 -0 1 1 1 -1 -0 1
Adjusted Earnings Per Share 2.1 2.1 1.1 -0.3 1.9 2 0.9 -1 -0.4 2

Unick Fix-A-Form Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 22 25 28 29 38 48 56 69 66 56 56 61
Other Income 0 0 0 0 0 0 1 1 1 1 0 0
Total Income 22 26 28 29 38 49 57 70 67 56 56 61
Total Expenditure 18 20 22 23 31 40 48 61 57 48 47 54
Operating Profit 4 5 6 6 7 8 9 9 9 8 9 8
Interest 1 1 1 1 2 2 2 2 2 2 2 4
Depreciation 1 2 2 2 3 3 4 4 4 4 4 4
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1 2 3 3 3 4 3 3 3 3 4 0
Provision for Tax 1 1 1 1 1 1 1 1 1 1 1 0
Profit After Tax 1 2 2 2 2 3 2 3 2 2 3 1
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 1 2 2 2 2 3 2 3 2 2 3 1
Adjusted Earnings Per Share 0 0 0 0 3.9 5.3 4.2 4.8 4.1 3.6 4.8 1.5

Unick Fix-A-Form Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 11 13 15 17 19 22 25 27 30 32 34
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 3 1 1 2 8 13 15 12 9 6 5
Other Non-Current Liabilities 2 2 2 2 2 3 3 3 3 4 4
Total Current Liabilities 14 15 13 14 16 21 20 28 29 31 28
Total Liabilities 30 31 31 36 46 59 63 71 71 73 71
Fixed Assets 17 17 16 18 26 36 36 41 39 38 36
Other Non-Current Assets 0 0 0 0 0 1 0 1 1 1 1
Total Current Assets 13 14 15 18 19 22 26 30 30 33 34
Total Assets 30 31 31 36 46 59 63 71 71 73 71

Unick Fix-A-Form Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 1 1 1 1 1 2 3 4 4 0
Cash Flow from Operating Activities 2 3 2 2 5 7 4 7 4 2 6
Cash Flow from Investing Activities -2 -1 -1 -4 -11 -13 -4 -8 -3 -2 -2
Cash Flow from Financing Activities 0 -2 -1 1 6 6 1 1 -2 0 -4
Net Cash Inflow / Outflow 0 0 -0 0 0 0 1 1 0 0 -0
Closing Cash & Cash Equivalent 1 1 1 1 1 2 3 4 4 4 0

Unick Fix-A-Form Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0 0 0 0 3.91 5.26 4.24 4.82 4.09 3.57 4.76
CEPS(Rs) 3.91 6.12 7.25 7.76 8.75 10.77 10.64 11.28 11.23 10.07 11.25
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0 0 0 0 35.28 40.57 44.85 49.7 53.44 56.72 62.28
Core EBITDA Margin(%) 16.9 20.06 21.52 20.16 18.88 16.71 14.69 12.12 13.26 13.9 16.01
EBIT Margin(%) 12.79 14.06 16.39 13.85 12.47 11.28 9.47 7.86 8.12 8.66 9.97
Pre Tax Margin(%) 6.68 9.3 12.53 10.56 8.53 8.15 5.53 4.89 4.52 4.67 6.28
PAT Margin (%) 4.3 6.28 8.04 7.97 5.6 5.96 4.15 3.8 3.39 3.5 4.66
Cash Profit Margin (%) 9.79 13.2 14.28 14.87 12.54 12.2 10.42 8.91 9.31 9.89 11.02
ROA(%) 3.15 5.23 7.26 6.81 5.24 5.54 3.82 3.94 3.17 2.73 3.64
ROE(%) 8.71 13.28 16.06 14.19 11.76 13.88 9.93 10.19 7.92 6.47 8
ROCE(%) 12.93 16.2 20.31 16.03 15.51 13.79 11.6 11.07 10.39 9.11 10.22
Receivable days 105.59 97.94 105.22 108.11 97.79 91.04 78.09 66.72 73 79.56 70.74
Inventory Days 63.03 53.36 37.85 31 27.77 30.39 35.74 40.88 53.15 81.55 104.44
Payable days 144.66 116.88 98.24 108.89 107.62 116.06 112.09 104.2 124.23 139.97 139.41
PER(x) 0 0 0 0 7.54 4.07 5.72 9.13 9.26 14.65 15.34
Price/Book(x) 0 0 0 0 0.83 0.53 0.54 0.88 0.71 0.92 1.17
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.71 0.53 0.43 0.48 0.79 0.66 0.59 0.64 0.6 0.86 1.01
EV/Core EBITDA(x) 3.86 2.5 1.92 2.31 4.09 3.76 3.75 4.96 4.29 5.7 6.21
Net Sales Growth(%) 25.77 16.14 9.48 2.76 33.67 26.55 15.71 23.95 -4.69 -15.65 0.29
EBIT Growth(%) 0.64 27.67 27.55 -13.13 20.32 14.45 -2.79 2.87 -1.61 -10.01 15.47
PAT Growth(%) -9.59 69.73 40.2 1.84 -6.05 34.66 -19.44 13.62 -15.15 -12.74 33.46
EPS Growth(%) 0 0 0 0 -6.05 34.66 -19.44 13.62 -15.15 -12.74 33.46
Debt/Equity(x) 0.97 0.72 0.52 0.55 0.81 0.99 0.92 0.89 0.77 0.74 0.61
Current Ratio(x) 0.9 0.93 1.16 1.25 1.2 1.06 1.3 1.04 1.05 1.06 1.22
Quick Ratio(x) 0.6 0.71 0.97 1.09 0.98 0.84 0.98 0.72 0.7 0.59 0.61
Interest Cover(x) 2.09 2.95 4.25 4.21 3.17 3.61 2.41 2.64 2.26 2.17 2.7
Total Debt/Mcap(x) 0 0 0 0 0.96 1.87 1.7 1 1.09 0.8 0.52

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 0% -7% +3% +10%
Operating Profit CAGR +13% 0% +2% +8%
PAT CAGR +50% 0% 0% +12%
Share Price CAGR -40% -8% -2% —
ROE Average +8% +7% +9% +11%
ROCE Average +10% +10% +10% +13%

Unick Fix-A-Form Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 71.57 %
FII 0 %
DII (MF + Insurance) 0.45 %
Public (retail) 27.99 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 71.5771.5771.5771.5771.5771.5771.5771.5771.5771.57
FII 0000000000
DII 0.450.450.450.450.450.450.450.450.450.45
Public 27.9927.9927.9927.9927.9927.9927.9927.9927.9927.99
Others 0000000000
Total 100100100100100100100100100100

Unick Fix-A-Form Peer Comparison

Pharmaceuticals & Drugs Edit Columns

Unick Fix-A-Form Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Unick Fix-A-Form Pros & Cons

Pros

  • Stock is trading at 0.6 times its book value
  • Debtor days have improved from 139.97 to 139.41days.
  • Company has reduced debt.

Cons

  • Company has a low return on equity of 7% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp